Natera presents 25 ESMO abstracts: what it means for Natera stock

Published on 10/28/2026 at 11:35 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Natera's ESMO summary reports 25 abstracts and 9 oral presentations on October 27, 2026. Natera stock costs EUR 370.55 on October 28, 2026.

ESMO findings broaden clinical evidence

Natera summarized 25 ESMO abstracts, including 9 oral presentations, on October 27, 2026.
Persistent Signatera negativity correlated with a 91.00 percent 24-month event-free survival rate in VOLGA.
Natera stock traded at EUR 370.55 at 11:32 a.m. CET at Lang & Schwarz on October 28, 2026.

NTRA, US6323071042, Illustration mit AI erstellt.

Natera (ISIN US6323071042) presented new oncology evidence from the European Society for Medical Oncology Congress, including 25 abstracts and 9 oral presentations. In its Business Wire release dated October 27, 2026, the company highlighted Signatera data from the phase III VOLGA trial in muscle-invasive bladder cancer.

What does the data mean?

The VOLGA analysis linked circulating tumor DNA status before radical cystectomy with 24-month event-free survival. Patients who remained Signatera-negative recorded a 91.00 percent rate, compared with 81.00 percent for patients who began positive but cleared their ctDNA and 55.00 percent for patients who remained positive, according to Natera's release.

The company also reported findings from lung, endometrial and breast cancer studies. In the MDT-BRIDGE lung study, Natera's Clarity MRD assay detected circulating tumor DNA in 99.00 percent of patients before treatment, while clearance at the second treatment cycle had an 83.00 percent predictive value for a complete pathological response.

Kidney data add a second catalyst

The oncology update follows a separate October 26, 2026 release on 18 abstracts presented at the American Society of Nephrology Kidney Week. Natera said one analysis found a median 5.30-year delay between the first abnormal kidney indicator and a documented chronic kidney disease diagnosis. Another found that only one third of high-risk patients had documented nephrology care.

Evidence now spans key programs

Together, the releases show a company building clinical evidence across oncology and organ health. The ESMO results offer quantified outcome differences in bladder cancer, while the Renasight findings identify a measurable diagnostic gap in kidney disease. Neither release establishes a commercial approval or revenue effect, so the investment relevance rests on further clinical validation and adoption.

Stock price in Berlin trading

Natera stock was trading at EUR 370.55 at Lang & Schwarz on October 28, 2026 at 11:32 a.m. CET. The latest company update therefore arrives alongside a live German-market indication, while the clinical figures remain the central new information.

The further course of trading is shown by the continuously updated real-time quote of Natera stock.